NASDAQ:NUVA NuVasive Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NuVasive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $50.67 +0.48 (+0.96%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$49.47▼$51.3650-Day Range$46.84▼$59.7252-Week Range$45.45▼$70.76Volume981,397 shsAverage Volume575,572 shsMarket Capitalization$2.64 billionP/E RatioN/ADividend YieldN/APrice Target$63.78 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NUVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVA Stock Forecast (MarketRank)Overall MarketRank™2.00 out of 5 starsMedical Sector596th out of 1,418 stocksSurgical & Medical Instruments Industry72nd out of 136 stocksAnalyst Opinion: 3.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 - 3.2 Analyst's Opinion Consensus RatingNuVasive has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 6 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $63.78, NuVasive has a forecasted upside of 25.9% from its current price of $50.67.Amount of Analyst CoverageNuVasive has only been the subject of 2 research reports in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesNuVasive has received 792 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNuVasive has received 346 “underperform” votes. (Add your “underperform” vote.)Community SentimentNuVasive has received 69.60% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote “Outperform” if you believe NUVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNuVasive does not currently pay a dividend.Dividend GrowthNuVasive does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuVasive insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $565,000.00 in company stock.Percentage Held by InsidersOnly 0.47% of the stock of NuVasive is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NuVasive are expected to grow by 12.12% in the coming year, from $2.31 to $2.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuVasive is -67.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuVasive is -67.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioNuVasive has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNuVasive has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NuVasive (NASDAQ:NUVA)NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.Read More NUVA Stock News HeadlinesJune 23, 2022 | finance.yahoo.comHARMONIC BIONICS EXPANDS LEADERSHIP TEAM WELCOMING NEW CHIEF FINANCIAL OFFICER AND CHIEF COMMERCIALIZATION & STRATEGY OFFICER - Yahoo FinanceJune 23, 2022 | americanbankingnews.comNuVasive (NASDAQ:NUVA) Shares Down 2.4% June 13, 2022 | seekingalpha.comNuVasive: Industry Tailwinds More Than Fairly PricedJune 10, 2022 | nasdaq.comWhy Is Perrigo (PRGO) Up 13.4% Since Last Earnings Report? - NasdaqJune 7, 2022 | businesswire.comGlobal Spinal Implants Markets Report 2022 with Profiles of B. Braun Melsungen, Depuy Synthes, Globus Medical, Lepu Medical Technology, Medtronic, Nuvasive, Stryker, & Zimmer Biomet - ResearchAndMarkets.com - Business WireJune 5, 2022 | nasdaq.comWhy Is NuVasive (NUVA) Up 6.3% Since Last Earnings Report? - NasdaqJune 3, 2022 | finance.yahoo.comWhy Is NuVasive (NUVA) Up 6.3% Since Last Earnings Report?June 3, 2022 | finance.yahoo.comSMAIO Receives FDA 510(k) Clearance for Its Balance Analyzer 3D Surgery Planning Software - Yahoo FinanceJune 2, 2022 | businesswire.comSMAIO Receives FDA 510(k) Clearance for Its Balance Analyzer 3D Surgery Planning Software - Business WireJune 1, 2022 | nasdaq.comFirst Week of July 15th Options Trading For Nuvasive (NUVA) - NasdaqMay 20, 2022 | benzinga.comNuVasive Earnings Perspective: Return On Invested Capital - Benzinga - BenzingaMay 17, 2022 | nasdaq.comNuvasive Breaks Above 200-Day Moving Average - Bullish for NUVAMay 10, 2022 | finance.yahoo.comIs NuVasive, Inc. (NASDAQ:NUVA) Trading At A 21% Discount?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:NUVA CUSIP67070410 CIK1142596 Webwww.nuvasive.com Phone(858) 909-1800Fax800-475-9134Employees2,900Year Founded1997Company Calendar Last Earnings5/04/2022Today6/24/2022Next Earnings (Estimated)7/27/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$63.78 High Stock Price Forecast$83.00 Low Stock Price Forecast$54.00 Forecasted Upside/Downside+25.9%Consensus RatingHold Rating Score (0-4)2.45454545454545 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E Ratio21.94 P/E Growth1.37Net Income$-64.09 million Net Margins-3.23% Pretax Margin-2.28% Return on Equity11.85% Return on Assets4.51% Debt Debt-to-Equity Ratio1.09 Current Ratio3.18 Quick Ratio1.88 Sales & Book Value Annual Sales$1.14 billion Price / Sales2.32 Cash Flow$4.89 per share Price / Cash Flow10.36 Book Value$15.37 per share Price / Book3.30Miscellaneous Outstanding Shares52,041,000Free Float51,796,000Market Cap$2.64 billion OptionableOptionable Beta1.11 Social Links NuVasive Frequently Asked Questions Should I buy or sell NuVasive stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares. View analyst ratings for NuVasive or view top-rated stocks. What is NuVasive's stock price forecast for 2022? 11 brokerages have issued twelve-month target prices for NuVasive's shares. Their NUVA stock forecasts range from $54.00 to $83.00. On average, they expect NuVasive's stock price to reach $63.78 in the next year. This suggests a possible upside of 25.9% from the stock's current price. View analysts' price targets for NuVasive or view top-rated stocks among Wall Street analysts. How has NuVasive's stock price performed in 2022? NuVasive's stock was trading at $52.48 at the beginning of 2022. Since then, NUVA stock has decreased by 3.4% and is now trading at $50.67. View the best growth stocks for 2022 here. When is NuVasive's next earnings date? NuVasive is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for NuVasive. How were NuVasive's earnings last quarter? NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings results on Wednesday, May, 4th. The medical device company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.16. The medical device company had revenue of $290.80 million for the quarter, compared to analyst estimates of $277.63 million. NuVasive had a positive trailing twelve-month return on equity of 11.85% and a negative net margin of 3.23%. The company's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the business earned $0.37 EPS. View NuVasive's earnings history. How will NuVasive's stock buyback program work? NuVasive declared that its board has approved a share buyback plan on Tuesday, November 9th 2021, which permits the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 3.5% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued. What guidance has NuVasive issued on next quarter's earnings? NuVasive updated its FY 2022 earnings guidance on Wednesday, May, 11th. The company provided earnings per share (EPS) guidance of $2.15-$2.45 for the period, compared to the consensus EPS estimate of $2.17. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.21 billion. Who are NuVasive's key executives? NuVasive's management team includes the following people: Mr. J. Christopher Barry, CEO & Director (Age 48, Pay $2.93M) (LinkedIn Profile)Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 52, Pay $939.39k)Mr. Dale A. Wolf, Sr. VP of Global Operations (Age 42, Pay $679.16k)Mr. Nathaniel B. Sisitsky Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $787.93k)Mr. Massimo Calafiore, Exec. VP & Chief Commercial Officer (LinkedIn Profile)Mr. Marc Rosenbaum, VP, Corp. Controller & Chief Accounting Officer (Age 50)Mr. Ryan Donahoe, Sr. VP & Chief Technology OfficerMr. Johnson Lai, Chief Information OfficerMs. Juliet C. Cunningham, VP of Investor RelationsMr. Michael Farrington, Sr. VP of Corp. Marketing, Brand & Communication What is Chris Barry's approval rating as NuVasive's CEO? 59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees. Who are some of NuVasive's key competitors? Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX). View all of NUVA's competitors. What other stocks do shareholders of NuVasive own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT). What is NuVasive's stock symbol? NuVasive trades on the NASDAQ under the ticker symbol "NUVA." Who are NuVasive's major shareholders? NuVasive's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.70%), Dimensional Fund Advisors LP (2.59%), Paradice Investment Management LLC (2.41%), Goldman Sachs Group Inc. (2.02%), Loomis Sayles & Co. L P (1.46%) and Fisher Asset Management LLC (1.44%). Company insiders that own NuVasive stock include Gregory T Lucier, James Christopher Barry, Lucas Vitale, Massimo Calafiore, Matthew Link and Paul Mcclintock. View institutional ownership trends for NuVasive. Which institutional investors are selling NuVasive stock? NUVA stock was sold by a variety of institutional investors in the last quarter, including Pier 88 Investment Partners LLC, Anchor Capital Advisors LLC, Paradice Investment Management LLC, Royal Bank of Canada, The Manufacturers Life Insurance Company , Rothschild & Co. Asset Management US Inc., SG Americas Securities LLC, and Vanguard Group Inc.. Company insiders that have sold NuVasive company stock in the last two years include James Christopher Barry, Lucas Vitale, and Massimo Calafiore. View insider buying and selling activity for NuVasive or view top insider-selling stocks. Which institutional investors are buying NuVasive stock? NUVA stock was acquired by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Nuance Investments LLC, Goldman Sachs Group Inc., Leeward Investments LLC MA, Frontier Capital Management Co. LLC, Woodline Partners LP, New York State Common Retirement Fund, and Canada Pension Plan Investment Board. View insider buying and selling activity for NuVasive or or view top insider-buying stocks. How do I buy shares of NuVasive? Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NuVasive's stock price today? One share of NUVA stock can currently be purchased for approximately $50.67. How much money does NuVasive make? NuVasive (NASDAQ:NUVA) has a market capitalization of $2.64 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64.09 million in net income (profit) each year or ($0.75) on an earnings per share basis. How many employees does NuVasive have? NuVasive employs 2,900 workers across the globe. Does NuVasive have any subsidiaries? The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.Read More When was NuVasive founded? NuVasive was founded in 1997. How can I contact NuVasive? NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for NuVasive is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at [email protected], or via fax at 800-475-9134. This page (NASDAQ:NUVA) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here